-
I-BET151 and the Next Frontier of Cancer Epigenetics
2026-08-16
A translational perspective on how I-BET151 (GSK1210151A) can help researchers interrogate BET-dependent transcription, super-enhancer biology, and disulfidptosis-related vulnerabilities in cancer models.
-
ERCC1 Deficiency, p53, and Cisplatin Response
2026-08-15
Heyza and colleagues used CRISPR-Cas9-engineered lung cancer models to show that the effect of ERCC1 deficiency on cisplatin response depends strongly on p53 status. Their results identify a synthetic-viable state in which p53 disruption, DNA-PKcs activity, and BRCA1 function help cells tolerate interstrand crosslink damage despite loss of ERCC1.
-
AZD1480: A Translational Compass for JAK2/STAT3
2026-08-14
AZD1480 provides a precise research framework for testing tumor-intrinsic JAK2/STAT3 signaling, particularly when immune-directed interventions increase IL-6-driven survival programs. This thought-leadership analysis connects its pharmacology with biomarker strategy, model selection, combination design, and the limitations that matter for translational oncology.
-
Hypoxia, FGFR1, and EGFR TKI Resistance in Lung Cancer
2026-08-14
Lu et al. show that sustained hypoxia can drive osimertinib resistance in NSCLC by increasing FGFR1 expression through MAPK signaling, promoting EMT and weakening BIM-mediated apoptosis. Genetic or pharmacologic inhibition of FGFR1 or MEK restored EGFR inhibitor activity in cell and xenograft models, identifying a microenvironment-linked resistance mechanism with clear experimental implications.
-
SR 11302: AP-1 Inhibition Workflows
2026-08-13
SR 11302 is a retinoid-independent AP-1 transcription factor inhibitor for separating AP-1 signaling from RAR/RXR activation. This guide translates cell proliferation, AP-1 reporter, and macrophage-polarization findings into practical workflows, controls, and troubleshooting decisions for cancer research.
-
Salinomycin: From Ionophore to Translational Tool
2026-08-13
Salinomycin is more than a cytotoxicity reagent: it is a mechanistically rich probe for studying transporter activity, Wnt/β-catenin signaling, calcium perturbation, proliferation, and apoptosis in hepatocellular carcinoma research. This article outlines how to convert those signals into more rigorous translational decisions.
-
Simvastatin, Autophagy, and Prostate Cancer
2026-08-12
The 2023 study by Miyazawa and colleagues identifies autophagy as a mechanistic axis of Simvastatin-mediated growth suppression in prostate cancer cell lines. Its combination of transcriptomic screening, orthogonal proliferation assays, autophagy measurements, and rapamycin perturbation provides a useful preclinical framework, while leaving questions about autophagic flux, selectivity, and in vivo efficacy unresolved.
-
GSK-923295: Mapping CENP-E Mitotic Phenotypes
2026-08-12
GSK-923295 is a potent CENP-E inhibitor for dissecting chromosome alignment, centromere function, and cell cycle arrest in mitosis. This article pairs pharmacological perturbation with CTCF-depletion findings to improve assay interpretation and cancer research decisions.
-
Dicoumarol Targets IRE1α in ER Stress Liver Injury
2026-08-11
Yang and colleagues developed a screening workflow that combines kinase-domain molecular docking with an XBP1s reporter assay to identify dicoumarol as an inhibitor of IRE1α activation. The study further links dicoumarol to protection against tunicamycin- and carbon tetrachloride-induced acute liver injury, providing a framework for discovering compounds that modulate ER stress signaling in hepatocytes.
-
Z-VAD-FMK Workflow for Apoptosis Studies
2026-08-11
Z-VAD-FMK provides a cell-permeable, irreversible pan-caspase intervention for separating caspase-dependent apoptosis from stress-associated cell death. This workflow connects apoptosis inhibition with ferroptosis-focused lens research while emphasizing timing, DMSO controls, orthogonal readouts, and interpretation limits.
-
(Z)-4-Hydroxytamoxifen: ER Biology to Relapse
2026-08-10
A translational perspective on how (Z)-4-Hydroxytamoxifen can sharpen estrogen receptor studies while informing the design, interpretation, and limitations of breast cancer relapse models.
-
InstaBlue Protein Stain Solution Protocol
2026-08-09
InstaBlue Protein Stain Solution provides rapid Coomassie-based visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is intended for protein electrophoresis analysis and compatible mass spectrometry workflows, but it should not be treated as a universal quantitative assay or as a substitute for protein identification methods.
-
CX-4945 for CK2 Cancer Research
2026-08-08
CX-4945 (Silmitasertib) enables a mechanism-led workflow for connecting CK2 activity with signaling, apoptosis, cell-cycle behavior, and lung cancer aggressiveness. This guide translates the ECE-1c/cisplatin-resistance study into practical assay design, dosing, controls, and troubleshooting strategies.
-
MLN4924 HCl Salt in Viral Immunity
2026-08-07
MLN4924 HCl salt offers translational researchers a selective way to interrogate NAE-dependent cullin-RING ligase activity, protein degradation, and immune signaling. This thought-leadership analysis connects neddylation pathway inhibition with viral RIPK3 degradation while distinguishing established evidence from testable hypotheses.
-
NU7441 (KU-57788): Precision DNA-PK Inhibition in Cancer Res
2026-08-07
Explore how NU7441 (KU-57788), a potent DNA-PK inhibitor, advances DNA repair and oncology research with unprecedented selectivity and practical insights. Discover unique assay guidance, translational opportunities, and what sets this molecule apart.